← Leaderboards
Peter A Campochiaro
Johns Hopkins University
$21,020,539
Attributed
$25,760,635
Total exposure
13
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,760,635 · 13
By mechanism
R01$23,120,007 · 8
UG1$1,374,929 · 1
R34$483,881 · 1
R21$448,964 · 1
R43$332,854 · 2
Top collaborators
- Laura Ensign6 shared
- Jordan Green6 shared
- John P Cooke4 shared
- Justin S. Hanes4 shared
- Xiangrong Kong2 shared
- Aleksander S. Popel2 shared
- Ming Yang2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Linda P Fried$18,538,317
- James T Handa$18,072,691
- Joseph Mark Savitt$880,771
- Gerald V Raymond$6,168,992
- Zahoor Ahmad Shah$2,990,250
Others in their field
Top investigators on “Blindness”
- Randall J Bateman · Washington University$137,189,188
- John M Lachin · George Washington University$122,970,601
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- Beth Baseler · Leidos Biomedical Research, Inc.$111,479,515
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$96,562,493
Research focus
BlindnessRetinaVascular Endothelial Growth FactorsPhotoreceptorsAnimal ModelMouse ModelDoseExtravasationBlood VesselsNeovascularizationRetinal DiseasesCessation Of LifeAngiogenesisSafetyPlayPreventLeadTherapeutic TargetGrantAge Related Macular DegenerationDiabetic RetinopathyChoroidal NeovascularizationCell DeathClinical Trials
Grant awards (64)
Topical delivery of HIF-1 inhibitors for retinal and choroidal vascular diseases$371,191
R01 · FY2025 · EY
Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of Action$329,375
R01 · FY2025 · EY · contact PI
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa$302,263
UG1 · FY2025 · EY · contact PI
Topical delivery of HIF-1 inhibitors for retinal and choroidal vascular diseases$436,695
R01 · FY2024 · EY
Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of Action$387,500
R01 · FY2024 · EY · contact PI
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa$302,263
UG1 · FY2024 · EY · contact PI
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists$598,945
R01 · FY2023 · EY · contact PI
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa$428,002
UG1 · FY2023 · EY · contact PI
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases$409,375
R01 · FY2023 · EY
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists$580,975
R01 · FY2022 · EY · contact PI
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases$397,094
R01 · FY2022 · EY
Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of Action$397,094
R01 · FY2022 · EY · contact PI
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa$342,401
UG1 · FY2022 · EY · contact PI
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists$580,975
R01 · FY2021 · EY · contact PI
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases$397,093
R01 · FY2021 · EY
Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of Action$397,093
R01 · FY2021 · EY · contact PI
Planning study for a phase-2 randomized multi-center placebo-controlled treatment trial of retinitis pigmentosa$238,256
R34 · FY2021 · EY
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists$598,945
R01 · FY2020 · EY · contact PI
Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of Action$409,375
R01 · FY2020 · EY · contact PI
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases$409,375
R01 · FY2020 · EY
Planning study for a phase-2 randomized multi-center placebo-controlled treatment trial of retinitis pigmentosa$245,625
R34 · FY2020 · EY
Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of Action$409,375
R01 · FY2019 · EY · contact PI
Biomaterial Inhibitor of HIF-1 for Prolonged Anti-Angiogenesis in Eye$422,481
R01 · FY2018 · EB
Biomaterial Inhibitor of HIF-1 for Prolonged Anti-Angiogenesis in Eye$422,481
R01 · FY2017 · EB
Sustained Suprachoroidal Delivery of Therapeutic Peptidesfor Ocular Diseases$204,401
R21 · FY2017 · EY
Biomaterial Inhibitor of HIF-1 for Prolonged Anti-Angiogenesis in Eye$422,481
R01 · FY2016 · EB
Sustained Suprachoroidal Delivery of Therapeutic Peptidesfor Ocular Diseases$244,563
R21 · FY2016 · EY
Biomaterial Inhibitor of HIF-1 for Prolonged Anti-Angiogenesis in Eye$422,481
R01 · FY2015 · EB
New Treatments of Ocular Neovascularization and Macular Edema$396,900
R01 · FY2015 · EY · contact PI
Oxidative Damage and Cone Cell Death in RP$568,291
R01 · FY2014 · EY · contact PI
New Treatments of Ocular Neovascularization and Macular Edema$396,900
R01 · FY2014 · EY · contact PI
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity$393,837
R01 · FY2014 · EY
Novel Biodegradable Injectable Rod for Improved AMD Therapy$187,358
R43 · FY2014 · EY
Controlled release of a multi-functional therapeutic for the treatment of AMD$145,496
R43 · FY2014 · EY
Oxidative Damage and Cone Cell Death in RP$544,101
R01 · FY2013 · EY · contact PI
New Treatments of Ocular Neovascularization and Macular Edema$384,750
R01 · FY2013 · EY · contact PI
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity$381,134
R01 · FY2013 · EY
Oxidative Damage and Cone Cell Death in RP$616,356
R01 · FY2012 · EY · contact PI
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity$405,202
R01 · FY2012 · EY
New Treatments of Ocular Neovascularization and Macular Edema$405,000
R01 · FY2012 · EY · contact PI
Oxidative damage and cone cell death in RP$594,587
R01 · FY2011 · EY · contact PI
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity$414,079
R01 · FY2011 · EY
Targeting survival factors for ocular neovascularization$378,240
R01 · FY2011 · EY · contact PI
Oxidative damage and cone cell death in RP$610,627
R01 · FY2010 · EY · contact PI
Targeting survival factors for ocular neovascularization$390,060
R01 · FY2010 · EY · contact PI
Oxidative damage and cone cell death in RP$621,980
R01 · FY2009 · EY · contact PI
Targeting survival factors for ocular neovascularization$394,000
R01 · FY2009 · EY · contact PI
Oxidative damage and cone cell death in RP$363,919
R01 · FY2009 · EY · contact PI
Targeting survival factors for ocular neovascularization$18,000
R01 · FY2009 · EY · contact PI
Oxidative damage and cone cell death in RP$508,409
R01 · FY2008 · EY · contact PI
Targeting survival factors for ocular neovascularization$386,120
R01 · FY2008 · EY · contact PI
Oxidative damage and cone cell death in RP$523,683
R01 · FY2007 · EY · contact PI
Targeting survival factors for ocular neovascularization$409,688
R01 · FY2007 · EY · contact PI
Molecular Signals Involved in Ocular Neovascularization$286,125
R01 · FY2005 · EY
FUNCTION OF PDGFS AND FGFS IN THE RETINA AND RPE$480,886
R01 · FY2004 · EY
Molecular Signals Involved in Ocular Neovascularization$286,125
R01 · FY2004 · EY
FUNCTION OF PDGFS AND FGFS IN THE RETINA AND RPE$550,264
R01 · FY2003 · EY
Molecular Signals Involved in Ocular Neovascularization$286,125
R01 · FY2003 · EY
FUNCTION OF PDGFS AND FGFS IN THE RETINA AND RPE$540,299
R01 · FY2002 · EY
Molecular Signals Involved in Ocular Neovascularization$286,125
R01 · FY2002 · EY
FUNCTION OF PDGFS AND FGFS IN THE RETINA AND RPE$497,791
R01 · FY2001 · EY
RETINAL NEOVASCULARIZATION IN DIABETIC RETINOPATHY$274,368
R01 · FY2001 · EY
FUNCTION OF PDGFS AND FGFS IN THE RETINA AND RPE$445,640
R01 · FY2000 · EY
RETINAL NEOVASCULARIZATION IN DIABETIC RETINOPATHY$279,997
R01 · FY2000 · EY